Literature DB >> 3739322

Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study.

T W Jungi, M Santer, P G Lerch, S Barandun.   

Abstract

Gamma-globulins for intravenous application (IgG-IV), processed by various methods, were tested for their ability to interact with human monocyte Fc receptors by determining the dose required to inhibit monocyte Fc receptor-mediated rosette formation and phagocytosis by half (ID50). Since dimeric and oligomeric IgG were found to be 2-3 times and 5-15 times more potent, respectively, than monomeric IgG, the varying proportions of polymeric IgG in intact IgG-IV were corrected for by calculation. The results of the rosette formation and phagocytosis tests were closely correlated, and insignificant differences between preparations processed by the same procedure were noted, while considerable differences were found between different procedures. The decreasing order of inhibitory activity was DEAE-Sephadex-treated IgG, acid-treated IgG, plasmin-digested IgG, polyethylene glycol(PEG)-precipitated IgG, IgG subjected to reduction/alkylation, IgG that underwent sulfitolysis, IgG treated with beta-propiolactone, and finally pepsin-treated IgG. Thus, while mild procedures preserve the capacity of IgG to interact with monocyte Fc receptors, chemical modification severely interferes with this important effector function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3739322     DOI: 10.1111/j.1423-0410.1986.tb00203.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  13 in total

Review 1.  Viral contamination of monoclonal antibody preparations: potential problems and possible solutions.

Authors:  C Harbour; G Woodhouse
Journal:  Cytotechnology       Date:  1990-07       Impact factor: 2.058

2.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

3.  Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin.

Authors:  N Kondo; T Ozawa; K Mushiake; F Motoyoshi; T Kameyama; K Kasahara; H Kaneko; M Yamashina; Y Kato; T Orii
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

4.  Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation.

Authors:  P A Thürmann; C Sonnenburg-Chatzopoulos; R Lissner
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

6.  The capacity of various types of immunoglobulin for intravenous use to interact with Fc receptors of human monocytes and macrophages.

Authors:  T W Jungi; J Eiholzer; P G Lerch; S Barandun
Journal:  Blut       Date:  1986-10

7.  Modulation of human monocyte Fc receptor function by surface-adsorbed IgG.

Authors:  T W Jungi; G von Below; P G Lerch; P J Spaeth
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

8.  Immunoglobulin Resistance in Kawasaki Disease.

Authors:  Georgios A Hartas; Syed Shahrukh Hashmi; Chi Pham-Peyton; Emmanouil Tsounias; John T Bricker; Monesha Gupta-Malhotra
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2015-03-01       Impact factor: 1.349

9.  Diffusion of immunoglobulins into rabbit cornea after subconjunctival injection: experimental demonstration and mathematical model.

Authors:  R Osusky; A Morell; P Imbach; P G Lerch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

Review 10.  In vitro effects of polyvalent immunoglobulin for intravenous use.

Authors:  I N van Schaik; M Vermeulen; A Brand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.